ASM's Top 5 TextbooksHelping educators teach tomorrow's microbiologists.
Dr. Bishai received his bachelor’s degree from Harvard in 1981 and a master’s degree from Cambridge University two years later. He returned to Harvard to earn both his medical degree and doctorate in 1989. He did his internship and residency at the Brigham and Women’s Hospital in Boston, Massachusetts, and received fellowship training in the Division of Infectious Diseases at the Johns Hopkins School of Medicine. He was a Howard Hughes Postdoctoral Research Fellow in the laboratory of Nobel laureate, Dr. Hamilton Smith. He joined the Johns Hopkins faculty in 1994 and is currently a Professor of Medicine in the Dept. of Medicine, Division of Infectious Diseases.
Dr. Bishai has been working on mechanisms of pathogenesis of M. tuberculosis and novel drugs and drug targets for TB for over 15 years as a faculty member at Johns Hopkins University School of Medicine where he serves as Co-director of the JHU Center for TB Research. He recruited Professor Jacques Grosset to Johns Hopkins in 2002, and together they have built a unit that is well-recognized for molecular analysis of M. tuberculosis and for testing drug combinations in the mouse and other animal models of TB. On Sept. 1, 2010 he became the Director of the KwaZulu Natal Research Institute for TB and HIV (K-RITH), an institute set up in a historic collaboration between the Howard Hughes Medical Institute (HHMI) and the University of KwaZulu Natal (UKZN) in Durban South Africa where there are large numbers of patients with TB, HIV and TB-HIV co-infection, K-RITH is setting up an inpatient unit in collaboration with McCord Hospital which will enable the lab to perform inpatient early bactericidal activity (EBA) studies of TB drugs in patients with active pulmonary TB.
He has authored over 150 papers in peer reviewed journals, and receives grant support from the National Institutes of Health. He serves on several editorial boards, review panels, and is the Co-Chair of the WHO Stop TB Partnership’s Working Group for New TB Drugs.